Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Advanced Malignant Neoplasm: early-phase trial registry

3 of 17 indexed Advanced Malignant Neoplasm trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,004 of 28,707 conditions by registered trial count.

17 US clinical trials · 3 currently recruiting · #1,004 of 28,707 conditions by registered trial count

Advanced Malignant Neoplasm: 17 US clinical trials tracked, 3 recruiting.

Advanced Malignant Neoplasm is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 12 of these trials.

Enrollment posture brief

Registry condition advanced-malignant-neoplasm

OPEN 3 | RECR 18% | LATE 1 | EARLY 9 | RANK #1004 | SPON 12

Nearest open-share peer: Cachexia (18% recruiting · 17 trials)

Acute Myeloid Leukemia, in R70.6%Abdominal Aortic Aneurysm52.9%Acute Lymphoblastic Leukemia23.5%Advanced Malignant Neopl (th…18%Actinic Keratosis11.8%
Open-enrollment share among volume-matched conditions near Advanced Malignant Neoplasm

Advanced Malignant Neoplasm lists 3 open slots (18% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Advanced Malignant Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Advanced Malignant Neoplasm is recruiting below its size-band peers.

    3 of 17 indexed trials (17.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Advanced Malignant Neoplasm research.

    M.D. Anderson Cancer Center accounts for 12 of 17 trials (70.6%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Advanced Malignant Neoplasm enrolment sits around 141 participants.

    Median target enrolment is 141 among the 17 trials that report a genuine target (sentinel values excluded). 5 of those (29.4%) plan for fewer than 100 participants.

  4. Advanced Malignant Neoplasm research is mostly interventional.

    15 interventional and 2 observational studies make up this index (88.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 23Phase 31

Open and recent trials

17 total, page 1 of 1

RECRUITING Phase 1 300 participants

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

PMV Pharmaceuticals

NCT04585750

RECRUITING Phase 1 263 participants

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology

NCT04067336

RECRUITING Phase 1 122 participants

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

AtlasMedx, Incorporated

NCT04503265

ACTIVE NOT RECRUITING NA 406 participants

Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center

M.D. Anderson Cancer Center

NCT03671226

ACTIVE NOT RECRUITING Phase 3 212 participants

A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy

M.D. Anderson Cancer Center

NCT03525873

ACTIVE NOT RECRUITING NA 207 participants

RCT of QPS vs General Information Sheet

M.D. Anderson Cancer Center

NCT03287492

ACTIVE NOT RECRUITING Phase 1 155 participants

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

NCT01552434

ACTIVE NOT RECRUITING Phase 2 150 participants

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

M.D. Anderson Cancer Center

NCT02286687

ACTIVE NOT RECRUITING 141 participants

Financial Distress in Advanced Cancer Patients

M.D. Anderson Cancer Center

NCT04053517

ACTIVE NOT RECRUITING Phase 1 120 participants

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Deciphera Pharmaceuticals

NCT03069469

ACTIVE NOT RECRUITING Phase 2 90 participants

Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer

M.D. Anderson Cancer Center

NCT02491632

ACTIVE NOT RECRUITING Phase 2 70 participants

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

M.D. Anderson Cancer Center

NCT03021486

ACTIVE NOT RECRUITING Phase 1 38 participants

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

M.D. Anderson Cancer Center

NCT03203525

ACTIVE NOT RECRUITING NA 27 participants

Cordotomy in Reducing Pain in Patients With Advanced Cancer

M.D. Anderson Cancer Center

NCT04119037

COMPLETED 351 participants

Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings

M.D. Anderson Cancer Center

NCT04186884

COMPLETED NA 125 participants

Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits

M.D. Anderson Cancer Center

NCT03856060

COMPLETED NA 41 participants

Enhancing Connections Program in Improving Communication Between Patients With Incurable Cancer and Their Children

University of Washington

NCT02650583

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 3
Phase 3 1

Named interventions

Most-linked intervention names on Advanced Malignant Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Questionnaire Administration Other
9 trials
Quality-of-Life Assessment Other
5 trials
Laboratory Biomarker Analysis Other
4 trials
Pharmacological Study Other
2 trials
Bevacizumab Biological
2 trials
Pegylated Liposomal Doxorubicin Hydrochloride Drug
1 trials
Cordotomy Procedure
1 trials
Physical Activity Other
1 trials

US sites by state

Facility locations filed on Advanced Malignant Neoplasm trials. A trial with sites in several states counts in each.

Texas 13 trials
California 4 trials
Tennessee 3 trials
New York 3 trials
Massachusetts 3 trials
Florida 3 trials
Pennsylvania 2 trials
Oregon 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Advanced Malignant Neoplasm page

17 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Malignant Neoplasm condition card totals 17 registered trials; most-linked intervention Questionnaire Administration; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.